Pharmaceutical Giant Richter Acquires Belgium-based Biotech Company [Video]

The pharmaceutical company’s newly inaugurated headquarters in Budapest

Gedeon Richter Plc. announced yesterday that it has acquired BCI Pharma, a Belgium-based privately-owned biotech company, carrying out innovative research activity in a variety of women’s health conditions.

The enterprise value implied by the transaction is EUR 12 million, payable over the next few years, subject to the achievement of development milestones, writes the pharmaceutical giant’s portal. BCI identifies new kinase inhibitors from its own kinase inhibitor library (small chemical molecules) and from its own database based on HTS (High-Throughput Screening).

Drug candidates are identified using state-of-the-art screening assays against clinically validated biological targets.

“BCI has applied its expertise in kinase research to identify highly valuable preclinical candidates,” noted Dr. Péter Turek, Head of Richter Women’s Healthcare (WHC). “This acquisition is a perfect strategic fit with our recently announced earlier deal, as it helps to frame our initial research expansion in the WHC territory located in Liège.”